Trillium Therapeutics (Toronto, ON)

CMDF Investment: $3,270,000.00
Focus: Infectious Dieases   Inflammatory Diseases  
www.trilliumtherapeutics.com

Trillium Therapeutics Inc. (TT) is a private immune therapy research and development company. TTI's focus is to develop therapies that restore balance to the immune system in conditions associated with abnormal and harmful immune responses; such as autoimmune and inflammatory disorders; viral hepatitis and transplant-related organ failure. TTI's business model is to identify therapeutic candidates with promising efficacy profiles in animal models and advance these into clinical testing. It is concentrating its activities on pre-clinical and early clinical development; with the primary objective of demonstrating safety and efficacy in humans. The company will seek development partners for late stage clinical trials.